Cargando…
Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study
Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945982/ https://www.ncbi.nlm.nih.gov/pubmed/35326339 http://dx.doi.org/10.3390/brainsci12030383 |
_version_ | 1784674084741709824 |
---|---|
author | Santos García, Diego Fernández Pajarín, Gustavo Oropesa-Ruiz, Juan Manuel Escamilla Sevilla, Francisco Rahim López, Raúl Rashid Abdul Muñoz Enríquez, José Guillermo |
author_facet | Santos García, Diego Fernández Pajarín, Gustavo Oropesa-Ruiz, Juan Manuel Escamilla Sevilla, Francisco Rahim López, Raúl Rashid Abdul Muñoz Enríquez, José Guillermo |
author_sort | Santos García, Diego |
collection | PubMed |
description | Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen’s effect size = −0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (−40.1%; p < 0.0001), mood/apathy (−46.6%; p = 0.001), gastrointestinal symptoms (−20.7%; p = 0.029), and miscellaneous (−44.94%; p = 0.021). QoL also improved with a 18.4% reduction in the 39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index (from 26.67 ± 17.61 at V0 to 21.75 ± 14.9 at V2; p = 0.001). A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%). Opicapone is well tolerated and improves global NMS burden and QoL in PD patients at 6 months. |
format | Online Article Text |
id | pubmed-8945982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89459822022-03-25 Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study Santos García, Diego Fernández Pajarín, Gustavo Oropesa-Ruiz, Juan Manuel Escamilla Sevilla, Francisco Rahim López, Raúl Rashid Abdul Muñoz Enríquez, José Guillermo Brain Sci Article Patients with Parkinson’s disease (PD) can improve some non-motor symptoms (NMS) after starting treatment with opicapone. The aim of this study was to analyze the effectiveness of opicapone on global NMS burden in PD. OPEN-PD (Opicapone Effectiveness on Non-motor symptoms in Parkinson’s Disease) is a prospective open-label single-arm study conducted in 5 centers from Spain. The primary efficacy outcome was the change from baseline (V0) to the end of the observational period (6 months ± 30 days) (V2) in the Non-Motor Symptoms Scale (NMSS) total score. Different scales were used for analyzing the change in motor, NMS, quality of life (QoL), and disability. Thirty-three patients were included between JUL/2019 and JUN/2021 (age 63.3 ± 7.91; 60.6% males; 7.48 ± 4.22 years from symptoms onset). At 6 months, 30 patients completed the follow-up (90.9%). The NMSS total score was reduced by 27.3% (from 71.67 ± 37.12 at V0 to 52.1 ± 34.76 at V2; Cohen’s effect size = −0.97; p = 0.002). By domains, improvement was observed in sleep/fatigue (−40.1%; p < 0.0001), mood/apathy (−46.6%; p = 0.001), gastrointestinal symptoms (−20.7%; p = 0.029), and miscellaneous (−44.94%; p = 0.021). QoL also improved with a 18.4% reduction in the 39-item Parkinson’s Disease Quality of Life Questionnaire Summary Index (from 26.67 ± 17.61 at V0 to 21.75 ± 14.9 at V2; p = 0.001). A total of 13 adverse events in 11 patients (33.3%) were reported, 1 of which was severe (not related to opicapone). Dyskinesias and nausea were the most frequent (6.1%). Opicapone is well tolerated and improves global NMS burden and QoL in PD patients at 6 months. MDPI 2022-03-12 /pmc/articles/PMC8945982/ /pubmed/35326339 http://dx.doi.org/10.3390/brainsci12030383 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Santos García, Diego Fernández Pajarín, Gustavo Oropesa-Ruiz, Juan Manuel Escamilla Sevilla, Francisco Rahim López, Raúl Rashid Abdul Muñoz Enríquez, José Guillermo Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study |
title | Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study |
title_full | Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study |
title_fullStr | Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study |
title_full_unstemmed | Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study |
title_short | Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson’s Disease: An Open-Label Prospective Study |
title_sort | opicapone improves global non-motor symptoms burden in parkinson’s disease: an open-label prospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8945982/ https://www.ncbi.nlm.nih.gov/pubmed/35326339 http://dx.doi.org/10.3390/brainsci12030383 |
work_keys_str_mv | AT santosgarciadiego opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy AT fernandezpajaringustavo opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy AT oropesaruizjuanmanuel opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy AT escamillasevillafrancisco opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy AT rahimlopezraulrashidabdul opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy AT munozenriquezjoseguillermo opicaponeimprovesglobalnonmotorsymptomsburdeninparkinsonsdiseaseanopenlabelprospectivestudy |